H Lundbeck A/S - Asset Resilience Ratio
H Lundbeck A/S (HLUN-B) has an Asset Resilience Ratio of -0.56% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2022)
This chart shows how H Lundbeck A/S's Asset Resilience Ratio has changed over time. See HLUN-B free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down H Lundbeck A/S's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is H Lundbeck A/S worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 0% |
| Short-term Investments | Dkr-208.00 Million | -0.56% |
| Total Liquid Assets | Dkr-208.00 Million | -0.56% |
Asset Resilience Insights
- Limited Liquidity: H Lundbeck A/S maintains only -0.56% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
H Lundbeck A/S Industry Peers by Asset Resilience Ratio
Compare H Lundbeck A/S's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940 |
Drug Manufacturers - Specialty & Generic | 9.11% |
Annual Asset Resilience Ratio for H Lundbeck A/S (2008–2022)
The table below shows the annual Asset Resilience Ratio data for H Lundbeck A/S.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | -0.52% | Dkr-195.00 Million ≈ $-30.51 Million |
Dkr37.45 Billion ≈ $5.86 Billion |
-0.13pp |
| 2021-12-31 | -0.39% | Dkr-134.00 Million ≈ $-20.97 Million |
Dkr34.65 Billion ≈ $5.42 Billion |
-0.10pp |
| 2020-12-31 | -0.29% | Dkr-104.00 Million ≈ $-16.27 Million |
Dkr36.03 Billion ≈ $5.64 Billion |
-0.30pp |
| 2019-12-31 | 0.01% | Dkr4.00 Million ≈ $625.83K |
Dkr35.76 Billion ≈ $5.59 Billion |
-13.16pp |
| 2018-12-31 | 13.17% | Dkr3.03 Billion ≈ $474.07 Million |
Dkr23.01 Billion ≈ $3.60 Billion |
+5.46pp |
| 2017-12-31 | 7.70% | Dkr1.52 Billion ≈ $238.13 Million |
Dkr19.76 Billion ≈ $3.09 Billion |
+7.62pp |
| 2016-12-31 | 0.08% | Dkr17.00 Million ≈ $2.66 Million |
Dkr20.21 Billion ≈ $3.16 Billion |
+0.00pp |
| 2015-12-31 | 0.08% | Dkr17.00 Million ≈ $2.66 Million |
Dkr21.32 Billion ≈ $3.34 Billion |
+0.01pp |
| 2014-12-31 | 0.07% | Dkr18.00 Million ≈ $2.82 Million |
Dkr25.64 Billion ≈ $4.01 Billion |
-4.34pp |
| 2013-12-31 | 4.41% | Dkr1.04 Billion ≈ $163.03 Million |
Dkr23.65 Billion ≈ $3.70 Billion |
-0.49pp |
| 2012-12-31 | 4.89% | Dkr1.05 Billion ≈ $165.06 Million |
Dkr21.56 Billion ≈ $3.37 Billion |
-2.30pp |
| 2011-12-31 | 7.19% | Dkr1.48 Billion ≈ $230.93 Million |
Dkr20.53 Billion ≈ $3.21 Billion |
+6.89pp |
| 2010-12-31 | 0.30% | Dkr54.00 Million ≈ $8.45 Million |
Dkr18.00 Billion ≈ $2.82 Billion |
-0.04pp |
| 2009-12-31 | 0.34% | Dkr59.00 Million ≈ $9.23 Million |
Dkr17.13 Billion ≈ $2.68 Billion |
-7.23pp |
| 2008-12-31 | 7.58% | Dkr955.00 Million ≈ $149.42 Million |
Dkr12.61 Billion ≈ $1.97 Billion |
-- |
About H Lundbeck A/S
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat maj… Read more